VISEN Pharmaceuticals (HK:2561)
:2561
Want to see HK:2561 full AI Analyst Report?
2561 Stock Chart & Stats
HK$33.68
--
Market closed
HK$33.68
--
Day’s Range― - ―
52-Week RangeHK$19.16 - HK$53.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)37.57K
Market Cap
HK$2.26B
Enterprise ValueHK$1.37B
Total Cash (Recent Filing)HK$805.91M
Total Debt (Recent Filing)HK$1.20M
Price to Earnings (P/E)―
Beta1.06
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding113,926,865
10 Day Avg. Volume36,930
30 Day Avg. Volume37,566
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)4.01
Price to Sales (P/S)19001.90
P/FCF Ratio-6.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Relatively Conservative Leverage / Balance SheetReported low-to-moderate leverage provides durable financial flexibility vs highly levered peers. This reduces near-term refinancing risk and helps preserve optionality to fund R&D or clinical programs, giving management time to pursue execution without immediate solvency pressure.
Positive Gross Profit In 2024–2025Sustained positive gross profit demonstrates underlying product economics and suggests unit-level margins are viable. If management stabilizes revenue and controls operating spend, positive gross margins create a credible path toward operating leverage and eventual profitability over a multi-quarter horizon.
Exposure To Specialty & Generic PharmaceuticalsOperating in specialty and generic pharmaceuticals ties the business to structurally resilient demand and recurring product needs. This industry positioning supports long-term revenue opportunities and strategic partnerships, and can underpin steady cash flows once commercial execution and cost discipline are established.
Bears Say
Persistent Large Operating LossesSustained negative EBIT and net losses erode equity and impair return generation, forcing constant reliance on external capital. Over months, continued operating losses increase dilution risk and limit reinvestment capacity, making the path to durable profitability uncertain without clear revenue recovery or cost restructuring.
Chronic Negative Operating And Free Cash FlowRecurring negative operating and free cash flow create ongoing cash burn that heightens dependence on financings. This structural cash shortfall can constrain R&D and commercialization, elevate refinancing risk if markets tighten, and force strategic concessions that weaken long-term competitive positioning.
Sharp Revenue Decline In 2025A material revenue drop reduces scale benefits and makes fixed costs harder to absorb, undermining margin improvement prospects. Over a multi-month horizon this suggests product adoption or market access issues that must be resolved to restore growth and justify continued investment.
VISEN Pharmaceuticals News
2561 FAQ
What was VISEN Pharmaceuticals’s price range in the past 12 months?
VISEN Pharmaceuticals lowest stock price was HK$19.16 and its highest was HK$53.80 in the past 12 months.
What is VISEN Pharmaceuticals’s market cap?
VISEN Pharmaceuticals’s market cap is HK$2.26B.
When is VISEN Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were VISEN Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is VISEN Pharmaceuticals overvalued?
According to Wall Street analysts VISEN Pharmaceuticals’s price is currently Overvalued.
Does VISEN Pharmaceuticals pay dividends?
VISEN Pharmaceuticals does not currently pay dividends.
What is VISEN Pharmaceuticals’s EPS estimate?
VISEN Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VISEN Pharmaceuticals have?
VISEN Pharmaceuticals has 113,926,865 shares outstanding.
What happened to VISEN Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VISEN Pharmaceuticals?
Currently, no hedge funds are holding shares in HK:2561
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VISEN Pharmaceuticals
VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Technical Analysis
HUTCHMED (China)
―
Hua Medicine
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
CanSino Biologics, Inc. Class H
―